Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Biomedika dan Kesehatan
Alsayed, Raghda
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Studi Banding tentang pengembangan vaksin untuk COVID-19 Alsayed, Raghda; Zainulabdeen, Khalid; Salman, Israa; Hairunisa, Nany; Amalia, Husnun; Yusop, Rahimi M; Redwan, Amamer M; Yousif, Emad
Jurnal Biomedika dan Kesehatan Vol 6 No 1 (2023)
Publisher : Fakultas Kedokteran Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/JBiomedKes.2023.v6.127-132

Abstract

The human respiratory system can be infected with coronaviruses (CoVs), one of the families of viruses that can lead to symptoms ranging from mild to fatal. Seven genera of CVS have been identified as having human infection to date. The virus can spread as fine, liquid particles from the mouth or nose of an infected person when coughing, sneezing, speaking, or breathing. The diameter of droplet particles ranges from large to small. In this review, we summarize vaccine development for COVID-19. We anticipate this study will be a valuable resource for any researcher interested in creating a COVID-19 vaccine.
Emerging Threats in the Age of Pandemics: A Focus on COVID-19 and the Novel Sub-Variant EG 5 ("Eris"): Review Article Alsayed, Raghda; Thamer, Hamsa; Hameed, Seenar; Kadhom, Mohammed; Hairunisa, Nany; Amalia, Husnun; Mashabi, Yasmine; Ahmed, Dina; Mahdi, Sarah; Husain, Amani; Salman, Israa; Yousif, Emad
Jurnal Biomedika dan Kesehatan Vol 7 No 2 (2024)
Publisher : Fakultas Kedokteran Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/JBiomedKes.2024.v7.262-267

Abstract

This paper draws attention to a recently identified sub-variant of SARS-CoV-2 known as EG 5, colloquially named "Eris," designated by the World Health Organization (WHO) as a variant of interest. The organization has urged nations to monitor and respond to the spread of this sub-variant since its identification on February 17, 2023. The discovery of the EG 5 variant, a sublineage of the Omicron variant, has introduced new challenges. Designated a "variant of interest" by the WHO, EG 5 carries distinctive genetic mutations, including an additional F456L amino acid mutation in the spike protein. Global prevalence has doubled, raising concerns about increased transmissibility. Although specific symptoms of EG 5 are not yet fully characterized, the variant has spread to 51 countries, with over 7,000 reported cases by August 15, 2023. The manuscript also explores the unique situation in Iraq, where, as of August 17, 2023, no EG 5 cases have been officially recorded. However, challenges such as self-treatment at. As the world grapples with the ongoing challenges of the COVID-19 pandemic, understanding the dynamics of emerging variants is crucial for effective public health responses and the development of targeted interventions.
Co-Authors Ahmed, Dina Hairunisa, Nany Hameed, Seenar Husain, Amani Husnun Amalia Kadhom, Mohammed Mahdi, Sarah Mashabi, Yasmine Redwan, Amamer M Salman, Israa Thamer, Hamsa Yousif, Emad Yusop, Rahimi M Zainulabdeen, Khalid